Loading…
Loading…
The Fund seeks to replicate, before fees and expenses, the price and yield performance of the ICE Intermediate AMT-Free Broad National Municipal Transition Index. The Intermediate Index is comprised of publicly traded municipal bonds that cover the US dollar denominated intermediate term tax-exempt bond market.
Is ITM's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precision Medicine up 30% YoY; Pixclara approval and pipeline advancements offer additional growth catalysts. The ITM acquisition, valued at $1.65 billion with up to $700 million in contingent payments, is expected to deliver $50 million in synergies and meaningful EBITDA from 2027.
Dose-response analysis from Phase 3 COMPETE trial shows an association between higher absorbed doses of ¹⁷⁷Lu-edotreotide in tumors and improved clinical response in GEP-NETsSeparate independent, investigator-led studies highlight promising clinical and translational data for Ga-DPI-4452, Tb-DOTA-LM3 and n. c. a. 177Lu-TTM Vienna, October 20, 2026 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that data supporting its targeted precision oncology portfolio were featured in three oral presentations and one e-poster at the European Association of Nuclear Medicine (EANM) 2026 Congress, held from October 17-21 in Vienna, Austria.
Vienna, October 20, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that data supporting its targeted precision oncology portfolio were featured in three oral presentations and one e-poster at the European Association of Nuclear Medicine (EANM) 2026 Congress, held from October 17-21 in Vienna, Austria. The presentations further support ITM's late- and early-stage radiopharmaceutical pipeline, highlighting novel therapeutic and diagnostic candidates across Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), clear cell Renal Cell Carcinoma (ccRCC), and glioblastoma. “The data presented at EANM 2026 underscore the therapeutic potential of our deep targeted radiopharmaceutical pipeline, which leverages different targets, both established and novel radioisotopes, and addresses several difficult-to-treat oncology indications,” said Dr. Celine Wilke, chief medical officer of ITM. “Whether derived from ITM's Phase 3 COMPETE trial or through the valuable insights of independent, investigator-initiated research, this growing evidence base supports the continued development of these novel radiopharmaceuticals across cancers with significant unmet medical need.” Higher Cumulative Tumor Absorbed Dose of 177Lu-edotreotide is Associated with Improved Clinical Response in GEP-NETs Dr. Anthime Flaus of the Hospices Civils de Lyon in Bron, France gave an oral presentation featuring a late-stage dose-response analysis from ITM's Phase 3 COMPETE trial evaluating non-carrier-added (n.c.a.) 177Lu-edotreotide (ITM-11) in patients with Grade 1 or 2 GEP-NETs. The analysis assessed the relationship between tumor cumulative absorbed dose and treatment response in 106 evaluable patients who received 4 treatment cycles of ¹⁷⁷Lu-edotreotide therapy. Higher cumulative tumor absorbed doses were associated with a better Best Overall Response (BOR). The Objective Response Rate (ORR) increased from 12% in the lowest dose quartile (Q1) to 64% in the highest dose quartile (Q4), with three complete responses occurring in patients with a cumulative dose above 86.1 Gy (Q3 and Q4). Cumulative tumor absorbed dose and tumor type were the main predictors of response in multivariate logistic regression models. Lesion-level analysis also identified a statistically significant association between absorbed dose and response. "The dosimetry data from the COMPETE trial offer insights into how tumor absorbed dose correlates with objective response," said Dr. Anthime Flaus, study author and physician at the Hospices Civils de Lyon. "Understanding this dose-response relationship provides important evidence that could potentially support the development of more individualized radiopharmaceutical treatment approaches, with the goal of optimizing patient care and outcomes." Early-Stage Pipeline Data Presented at EANM 2026 The conference also highlighted promising clinical and translational data supporting the further development of other ITM pipeline candidates. These data, derived from independent trials and research initiated by investigators, offer valuable clinical insights to support the further development of ITM candidates currently in Phase 1 trials, including: Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, or CAIX peptide), an investigational diagnostic imaging agent for ccRCC; [161Tb]Tb-DOTA-LM3 (Tb-DOTA-LM3) as a potential therapeutic for somatostatin receptor (SSTR)-positive tumors; and n.c.a. 177Lu-TTM for intra-cavitary immunoradiotherapy in patients with glioblastoma. Ga-DPI-4452 Demonstrates High Tumor Uptake and Superior Detection of ccRCC Compared to Conventional CT Dr. Alina Küper of the Department of Nuclear Medicine at University Hospital Essen in Germany highlighted in an oral presentation the interim results from an independent bicenter retrospective registry evaluating Ga-DPI-4452 PET/CT for imaging 98 patients with suspected or proven ccRCC. In the analysis, Ga-DPI-4452 demonstrated abnormal findings in 91.8% of patients with subsequently confirmed ccRCC. Additionally, Ga-DPI-4452 exhibited high tumor uptake and superior detection efficacy across 153 predefined anatomical regions compared to conventional CT imaging, including in renal primary tumors/recurrence, regional lymph nodes, distant lymph nodes, bone metastases, and visceral metastases. Lower Peptide Mass of [161Tb]Tb-DOTA-LM3 Increases Tumor Absorbed Dose in Metastatic GEP-NETs In an oral presentation, Dr. Julia G. Fricke and Prof. Damian Wild, Physician-Scientists and Researchers in Nuclear Medicine and Theranostics at the University Hospital Basel, Switzerland, shared safety, dosimetry, and preliminary efficacy data from the Phase 0b BETA PLUS study for the SSTR2 antagonist [161Tb]Tb-DOTA-LM3. In the study evaluating dosimetry in 6 patients with metastatic GEP-NETs, a peptide mass-dependent effect was observed, wherein a lower peptide mass (
ITM Power PLC (AIM:ITM), the green hydrogen technology company, increased annual revenue by 68% to £43.6 million and cut its adjusted earnings losses by 39% as it expanded its project pipeline and secured government backing for new manufacturing capacity. The London-listed company reported an adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) loss of £20.2 million for the financial year to 30 April, down from £33 million a year earlier, with revenue rising from £26 million.
ITM Power PLC (AIM:ITM), the green hydrogen technology company, said its Hydropulse subsidiary has signed preliminary terms with a European oil refinery for a 150 megawatt project that could become its largest commercial commitment to date. The proposed development would use ITM Power's Alpha electrolyser platform to produce green hydrogen on site under a 10-year agreement.